Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11126 - 11150 of 12824 in total
AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.
Investigational
ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Investigational
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
Matched Description: … ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain …
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
Matched Description: … It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated …
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Investigational
Matched Description: … It is developed by AstraZeneca and is currently in phase I/II trials. …
AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity.
Investigational
Matched Description: … It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. …
Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease. Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture.
Investigational
Matched Description: … dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in ... lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture ... Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated …
CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Investigational
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to millions of asthma and allergy patients.
Investigational
trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Investigational
Matched Description: … trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial …
TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
Investigational
Matched Description: … TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the ... It is expected to be developed as a potential treatment to prevent blood clot formation in connection …
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase …
YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Investigational
Matched Description: … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in ... In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side …
AB192 is a DPP IV enzymatic activity inhibitor.
Experimental
IR502 (Zorcell) is a potential treatment for psoriasis.
Investigational
Investigational
Investigational
Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. [MeSH]
Investigational
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
Investigational
Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
Investigational
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. ALTU-135 has been granted orphan drug...
Investigational
Matched Description: … consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in
Displaying drugs 11126 - 11150 of 12824 in total